<DOC>
	<DOCNO>NCT02489409</DOCNO>
	<brief_summary>Endostatin widely apply clinical treatment partial primary metastatic solid tumor . Endostatin combine chemotherapy achieve favorable progression treatment non-small cell lung cancer ( NSCLC ) . However , research efficacy Endostatin breast cancer start . Breast cancer highly-differentiated solid tumor , indicate also indicator Endostatin therapy . Additionally , chemo- radiotherapy , primary nidus patient advance breast cancer may also lead rapid development tumor location . So Endostatin combine chemotherapy also improve prognosis patient recurrent metastatic breast cancer , rare report home abroad . To explore research , study design randomize , open control clinical study observe clinical efficacy EndostarTM Injection combine GP/NP/GX/NX treatment recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Recombinant Human Endostatin ( EndostarTM ) Injection Treatment Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Age : 18～70 year old ; Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) score : 0～1 score ; All patient diagnose recurrent metastatic breast cancer retreatment histopathology compute tomography ( CT ) examination ; The measurable nidus≥1 : Patients whose nidus diameter ≥ 20 mm normal CT magnetic resonance image ( MRI ) scanning , ≥ 10 mm spiral CT scanning ; Patients whose blood routine , hepatorenal function , electrolyte cardiac function basically normal without dysfunction primary organ . White blood cell count ( WBC ) ≥4.0×109/L , neutrophile granulocyte count ≥1.5×109/L , platelet ( PLT ) count ≥100×109/L , hemoglobin ( HGB ) ≥95 g/L , serum bilirubin ( BIL ) ≤1.5fold upper limit normal value , alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤2fold upper limit normal value , serum creatinine ( Scr ) ≤1.5mg/dl ; The expect survival time ＞3 month ; Patients could understand study status sign inform consent form . Patients history allergic response biological agent ; Patients receive antitumor therapy ; Patients without measureable nidus ; Others , include one following condition : patient uncontrolled central nervous system ( CNS ) metastatic nidus , dysfunction important organ severe cardiac disease ( congestive heart failure , uncontrollable arrhythmia , angina pectoris , valvular heart disease , myocardial infarction refractory hypertension require longterm drug administration ) , chronic infectious wound history uncontrollable psychosis , woman pregnant lactation period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>